We are an independent company set up by a team of pharmaceutical industry professionals focused on identifying and exploring opportunities emerging in Polish and CEE markets.

Our diverse and complementary experience was gained at several, global pharmaceutical companies, in Poland and abroad, where we held top leadership as well as key specialist roles. Our collective background spans product development, clinical research, regulatory as well as marketing and sales.

At Ethifarm we are positioned to utilize our professional knowledge and diversified experience in an optimal way - fully empowered by the entrepreneurial flexibility our organization offers, and avoiding limitations often imposed by large, corporate structures.

We have demonstrated successfully our ability to work effectively on the development of new products and related technology transfers with multiple partners, both in Poland and abroad.

Our growth strategy, although rooted in our own core competencies can be strongly enhanced through cooperation with third parties (in-licensing) and outsourcing, particularly in the areas of contract manufacturing, sales and marketing. We believe that such an ability to collaborate and create synergies between business partners is a significant advantage in the pharmaceutical market today.

At Ethifarm, we are excited about exploring such opportunities and are looking to make the most of them.

Since 2008, when Ethifarm started its operations, we introduced two new products on to Polish market, having no equivalents in the CEE at the time of their launch: a generic of modified release trimetazidine (Cyto-Protectin MR) and a softgel diosmine formulation (Diosminal).
Although we are strongly committed to the further development of our own formulations, we also believe that both - acquisition of the new brands as well as in-licensing may prove to be efficient tools in building up a truly competitive portfolio of products for Ethifarm .

Consequently, our core activities include :

• development and registration of the new formulations as well as acquisition / in-licensing of the new brands
• their distribution and direct sales to the retail sector ( pharmacies ), enhanced by
• marketing and promotional support within the health care professionals community

all these are performed with a strategic objective to build up a strong market position as well as an efficient, integrated supply chain for our products, straight from the manufacturing site right to the pharmacy shelf.

Ethifarm, based in Poznań ( western Poland ) has been founded in 2004.
The company's ownership structure has not been changed since then and Ethifarm remains to be owned by the three members of its Executive Board.
The milestones in our history can be best described as follows :

• July 2008 - launch of the first product on the domestic market , Cyto-Protectin MR ( modified-release trimetazidine )
• July 2010 - a soft gel diosmin formulation (Diosminal) has been introduced.
• Jan 2011 - the Wholesale Unit started its operations and first direct sales to retailers took place
• Q4 of 2011 - 3 new products were acquired from Curtis Healthare, all of them already marketed in Poland ( please see Products section for details )
• Q4 of 2011 - Diosminal has been granted marketing approval in Russia, Belorussia,Ukraine and Kazakhstan adding an international dimension to the company's business activities

Over the past 3 years, since the very start of its operations, the Ethifarm turnover was growing at the average rate of 40 % per annum, which was achieved entirely by the sales of the 2 products developed by the company itself - Diosminal and Cyto-Protectin MR.